Markets:

Overview

News

Currencies

International

Treasuries

BioRestorative Therapies, Inc. - Common Stock (NQ:BRTX)

0.2251 -0.1875 (-45.44%)

Streaming Delayed Price Updated: 11:28 AM EST, Feb 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about BioRestorative Therapies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years? ↗

March 21, 2023

Successful Autologous Cell-Based Therapies

Via Benzinga

EXCLUSIVE: BioRestorative Seeks Expanded FDA Approval For BRTX-100 Clinical Application, Engages Advisory Firm ↗

March 13, 2023

BioRestorative Therapies Inc (NASDAQ: BRTX) has entered into an agreement with Bruder Consulting & Venture Group, a full-service strategic advisory, to assist the company in seeking FDA approval for...

Via Benzinga

BRTX's ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome ↗

March 08, 2023

Metabolism is the chemical process whereby the body produces energy from food. By breaking down carbohydrates and fats into sugars, the cells access fuel that can be used or stored via the liver or...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

March 06, 2023

Via Benzinga

Why BioRestorative Therapies Stock Is Climbing Higher Today ↗

March 02, 2023

BioRestorative Therapies, Inc.

Via Benzinga

Dow Jumps Over 300 Points; Best Buy Profit Beats Views ↗

March 02, 2023

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 300 points on Thursday. The Dow traded up 0.97% to 32,978.95 while the NASDAQ rose 0.59% to 11,446.55. The S&P...

Via Benzinga

Why Cano Health Shares Are Trading Lower By Around 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

March 02, 2023

Gainers Exela Technologies, Inc. (NASDAQ: XELA) shares surged 45% to $0.0701 after the company announced $51 million of new funding, amendment increases existing securitization facility to $185 million...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

March 02, 2023

Via Benzinga

Dow Rises 100 Points; Macy's Posts Upbeat Earnings ↗

March 02, 2023

U.S. stocks traded mixed midway through trading, with the Dow Jones gaining around 100 points on Thursday. The Dow traded up 0.31% to 32,764.50 while the NASDAQ fell 0.49% to 11,324.28. The S&P 500...

Via Benzinga

BioRestorative Therapeutics (BRTX) Stock Soars 40% on Patent News ↗

March 02, 2023

Could more patents translate to more revenue for BioRestorative Therapeutics? It's a question that BRTX stock traders are considering now.

Via InvestorPlace

Wall Street Mixed At Open; US Weekly Jobless Claims Decline ↗

March 02, 2023

U.S. stocks traded mixed this morning, with the Dow Jones gaining around 80 points on Thursday. Following the market opening Thursday, the Dow traded up 0.24% to 32,740.88 while the NASDAQ fell 0.58%...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

March 02, 2023

Via Benzinga

EXCLUSIVE: BioRestorative To Receive Third US Patent For Metabolic ThermoStem Program ↗

March 02, 2023

The United States Patent and Trademark Office has issued a notice of allowance for a patent application related to BioRestorative Therapies Inc's (NASDAQ: BRTX) metabolic ThermoStem program.

Via Benzinga

BioRestorative Therapies: This Biopharma Company Is Helping Your Body Heal Itself ↗

February 16, 2023

Lance Alstodt, Chairman and CEO of BioRestorative Therapies, Inc. (NASDAQ: BRTX), was recently interviewed by Benzinga.

Via Benzinga

BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes

February 10, 2023

BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes

Via News Direct

Topics Intellectual Property

BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes ↗

February 10, 2023

BioRestorative Therapies (NASDAQ: BRTX), a clinical-stage biotechnology company focused on stem cell-based therapies, announced on the 8th of February that the European Patent Office had issued a...

Via Benzinga

EXCLUSIVE: BioRestorative Poised To Receive European Patent For ThermoStem Program ↗

February 08, 2023

The European Patent Office has issued a notice of allowance for a patent application related to BioRestorative Therapies Inc's (NASDAQ: BRTX) metabolic ThermoStem program. The notice of allowance was...

Via Benzinga

BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results

February 03, 2023

BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results

Via News Direct

BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results ↗

February 03, 2023

Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony...

Via Benzinga

2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies

January 26, 2023

2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies

Via News Direct

2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies ↗

January 25, 2023

BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development.

Via Benzinga

EXCLUSIVE: BioRestorative Secures Funding Support For Programs Against Polycystic Ovary Syndrome ↗

December 06, 2022

BioRestorative Therapies Inc (NASDAQ: BRTX) has received a Small Business Innovation Research (SBIR) Phase I grant from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development...

Via Benzinga

EXCLUSIVE: BioRestorative Therapies Gets Exclusive License Rights From Regenexx For Development Of BRTX-100 Disc Program To Treat Chronic Lumbar Disc Disease ↗

December 05, 2022

BioRestorative Therapies, Inc (NASDAQ: BRTX), a stem cell-based therapies clinical-stage company, forged an agreement with Regenexx, LLC, under which BRTX gets exclusive license rights for intellectual...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 23, 2022

Via Benzinga

The NIH Has Given BioRestorative Therapies A Stamp Of Approval

November 10, 2022

By Faith Ashmore, Benzinga

Via News Direct

The NIH Has Given BioRestorative Therapies A Stamp Of Approval ↗

November 09, 2022

BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes.

Via Benzinga

See What's Next For The Regenerative Medicine Field -- BioRestorative Intends to Lead The Pack In Stem Cell Therapies! ↗

October 28, 2022

While stem cell therapy has always been a more controversial topic, as the general public has gained more knowledge on the practice and induced pluripotent stem (iPS) cells have gained traction in...

Via Benzinga

A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field

October 14, 2022

By David Willey, Benzinga

Via News Direct

A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field ↗

October 13, 2022

Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems.

Via Benzinga

Why Senti Biosciences Shares Jumped Over 50%; Here Are 79 Biggest Movers From Yesterday ↗

September 30, 2022

Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares climbed 50.7% to close at $2.11 on Thursday after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target.

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

BioRestorative Therapies, Inc. - Common Stock (NQ:BRTX)

Headline News about BioRestorative Therapies, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today